Individuals seeking effective weight management methods can seek medical advice from the team at Primary Care of Clear Lake, where Dr
Novo Nordisk A/S 17.9.2025 23:05:02 CEST | Globenewswire | Press release Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy ) achieved significant weight loss, with one in three study participants losing 20% or more body weight 1 ** Oral semaglutide 25 mg also demonstrated improvements in the ability to perform everyday physical activities such as bending, standing, walking, being physically active, and improvements in cardiovascular risk factors 1 Oral semaglutide 25 mg is the first oral GLP-1 therapy submitted to the US Food and Drug Administration (FDA) for chronic weight management, 2 and Novo Nordisk has already begun production at its US sites Bagsvrd, Denmark, Plainsboro, NJ, 17 September 2025 Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the investigational once-daily oral semaglutide 25 mg (Wegovy in a pill * ), marking a significant milestone in the companys ambition to advance obesity care
Once injected, semaglutide remains active in the body for an extended period, allowing once-weekly dosing for many patients
AN: Writing review and editing
Are GLP-1 medications safe for long-term use
